Haematopoietic cell kinase (Hck) is a protein tyrosine kinase of the Src family specifically expressed in phagocytes as two isoforms, p59Hck and p61Hck, present at the plasma membrane and lysosomes, respectively. We report that ectopic expression of a constitutively active mutant of p61Hck (p61Hck ca ) triggered the de novo formation of actin-rich rings at the ventral face of the cells that we characterized as bona fide podosome rosettes, structures involved in cell migration. Their formation required the adaptor domains and the kinase activity of p61Hck, the integrity of microfilament and microtubule networks and concerted action of Cdc42, Rac and Rho. Podosome rosette formation was either abolished when p61Hck ca was readdressed from lysosomes to the cytosol or triggered when p59Hck ca was relocalized to lysosomes. Lysosomal markers were present at podosome rosettes. By stimulating exocytosis of p61Hck ca lysosomes with a calcium ionophore, the formation of podosome rosettes was enhanced. Interestingly, we confirm that, in human macrophages, Hck and lysosomal markers were present at podosomes which were spatially reorganized as clusters, a foregoing step to form rosettes, upon expression of p61Hck ca . We propose that lysosomes, under the control of p61Hck, are involved in the biogenesis of podosomes, a key phenomenon in the migration of phagocytes.
Infections caused by carbapenem-resistant (CRE) are increasingly prevalent and have become a major worldwide threat to human health. Carbapenem resistance is driven primarily by the acquisition of β-lactamase enzymes, which are able to degrade carbapenem antibiotics (hence termed carbapenemases) and result in high levels of resistance and treatment failure. Clinically relevant carbapenemases include both serine β-lactamases (SBLs; e.g., KPC-2 and OXA-48) and metallo-β-lactamases (MBLs), such as NDM-1. MBL-producing strains are endemic within the community in many Asian countries, have successfully spread worldwide, and account for many significant CRE outbreaks. Recently approved combinations of β-lactam antibiotics with β-lactamase inhibitors are active only against SBL-producing pathogens. Therefore, new drugs that specifically target MBLs and which restore carbapenem efficacy against MBL-producing CRE pathogens are urgently needed. Here we report the discovery of a novel MBL inhibitor, ANT431, that can potentiate the activity of meropenem (MEM) against a broad range of MBL-producing CRE and restore its efficacy against an NDM-1-producing strain in a murine thigh infection model. This is a strong starting point for a chemistry lead optimization program that could deliver a first-in-class MBL inhibitor-carbapenem combination. This would complement the existing weaponry against CRE and address an important and growing unmet medical need.
The
clinical effectiveness of carbapenem antibiotics such as meropenem
is becoming increasingly compromised by the spread of both metallo-β-lactamase
(MBL) and serine-β-lactamase (SBL) enzymes on mobile genetic
elements, stimulating research to find new β-lactamase inhibitors
to be used in conjunction with carbapenems and other β-lactam
antibiotics. Herein, we describe our initial exploration of a novel
chemical series of metallo-β-lactamase inhibitors, from concept
to efficacy, in a survival model using an advanced tool compound (ANT431)
in conjunction with meropenem.
The clinical effectiveness of the
important β-lactam class of antibiotics is under threat by the
emergence of resistance, mostly due to the production of acquired
serine- (SBL) and metallo-β-lactamase (MBL) enzymes. To address
this resistance issue, multiple β-lactam/β-lactamase inhibitor
combinations have been successfully introduced into the clinic over
the past several decades. However, all of those combinations contain
SBL inhibitors and, as yet, there are no MBL inhibitors in clinical
use. Consequently, there exists an unaddressed yet growing healthcare
problem due to the rise in recent years of highly resistant strains
which produce New Delhi metallo (NDM)-type metallo-carbapenemases.
Previously, we reported the characterization of an advanced MBL inhibitor
lead compound, ANT431. Herein, we discuss the completion of a lead
optimization campaign culminating in the discovery of the preclinical
candidate ANT2681, a potent NDM inhibitor with strong potential for
clinical development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.